These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26761771)

  • 1. Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Schweitzer M; Makhoul S; Paliouras M; Beitel LK; Gottlieb B; Trifiro M; Chowdhury SF; Zaman NM; Wang E; Davis H; Chalifour LE
    Atherosclerosis; 2016 Mar; 246():78-86. PubMed ID: 26761771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.
    Zambrano T; Saavedra N; Lanas F; Caamaño J; Salazar LA
    Mol Diagn Ther; 2015 Feb; 19(1):45-52. PubMed ID: 25589339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
    Davis HR; Veltri EP
    J Atheroscler Thromb; 2007 Jun; 14(3):99-108. PubMed ID: 17587760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.
    Hawes BE; O'neill KA; Yao X; Crona JH; Davis HR; Graziano MP; Altmann SW
    Mol Pharmacol; 2007 Jan; 71(1):19-29. PubMed ID: 17005902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.
    Lauridsen BK; Stender S; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    Eur Heart J; 2015 Jul; 36(25):1601-8. PubMed ID: 25841872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular loop C of NPC1L1 is important for binding to ezetimibe.
    Weinglass AB; Kohler M; Schulte U; Liu J; Nketiah EO; Thomas A; Schmalhofer W; Williams B; Bildl W; McMasters DR; Dai K; Beers L; McCann ME; Kaczorowski GJ; Garcia ML
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11140-5. PubMed ID: 18682566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene polymorphism and frequencies of the NPC1L1 gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia.
    Kashiwabara Y; Kobayashi Y; Koba S; Kohyama N; Ohbayashi M; Murayama JI; Hirano T; Kobayashi Y; Yamamoto T
    J Clin Pharm Ther; 2014 Oct; 39(5):551-4. PubMed ID: 24861377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.
    Ge L; Wang J; Qi W; Miao HH; Cao J; Qu YX; Li BL; Song BL
    Cell Metab; 2008 Jun; 7(6):508-19. PubMed ID: 18522832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The c.-133A > G polymorphism in NPC1L1 gene influences the efficacy of ezetimibe monotherapy on apolipoprotein A1 in hyperlipidemic patients.
    Zsíros N; Bodor M; Varga V; Berta E; Balogh I; Seres I; Paragh G; Harangi M
    Pharmazie; 2014 Jun; 69(6):424-9. PubMed ID: 24974575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels.
    Xie P; Zhu H; Jia L; Ma Y; Tang W; Wang Y; Xue B; Shi H; Yu L
    Atherosclerosis; 2014 Dec; 237(2):609-17. PubMed ID: 25463095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe.
    Wang J; Williams CM; Hegele RA
    Clin Genet; 2005 Feb; 67(2):175-7. PubMed ID: 15679830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.
    Simon JS; Karnoub MC; Devlin DJ; Arreaza MG; Qiu P; Monks SA; Severino ME; Deutsch P; Palmisano J; Sachs AB; Bayne ML; Plump AS; Schadt EE
    Genomics; 2005 Dec; 86(6):648-56. PubMed ID: 16297596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fomiroid A, a novel compound from the mushroom Fomitopsis nigra, inhibits NPC1L1-mediated cholesterol uptake via a mode of action distinct from that of ezetimibe.
    Chiba T; Sakurada T; Watanabe R; Yamaguchi K; Kimura Y; Kioka N; Kawagishi H; Matsuo M; Ueda K
    PLoS One; 2014; 9(12):e116162. PubMed ID: 25551765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe.
    Temel RE; Tang W; Ma Y; Rudel LL; Willingham MC; Ioannou YA; Davies JP; Nilsson LM; Yu L
    J Clin Invest; 2007 Jul; 117(7):1968-78. PubMed ID: 17571164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal domain of the cholesterol transporter Niemann-Pick C1-like 1 (NPC1L1) is essential for α-tocopherol transport.
    Kamishikiryo J; Haraguchi M; Nakashima S; Tasaka Y; Narahara H; Sugihara N; Nakamura T; Morita T
    Biochem Biophys Res Commun; 2017 Apr; 486(2):476-480. PubMed ID: 28315682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NPC1L1: evolution from pharmacological target to physiological sterol transporter.
    Huff MW; Pollex RL; Hegele RA
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2433-8. PubMed ID: 16973966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niemann-pick C1-like 1 mediates alpha-tocopherol transport.
    Narushima K; Takada T; Yamanashi Y; Suzuki H
    Mol Pharmacol; 2008 Jul; 74(1):42-9. PubMed ID: 18403720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).
    Garcia-Calvo M; Lisnock J; Bull HG; Hawes BE; Burnett DA; Braun MP; Crona JH; Davis HR; Dean DC; Detmers PA; Graziano MP; Hughes M; Macintyre DE; Ogawa A; O'neill KA; Iyer SP; Shevell DE; Smith MM; Tang YS; Makarewicz AM; Ujjainwalla F; Altmann SW; Chapman KT; Thornberry NA
    Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8132-7. PubMed ID: 15928087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibe-sensitive cholesterol uptake into the intestinal brush border membrane.
    Knöpfel M; Davies JP; Duong PT; Kvaernø L; Carreira EM; Phillips MC; Ioannou YA; Hauser H
    Biochim Biophys Acta; 2007 Sep; 1771(9):1140-7. PubMed ID: 17689140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.